FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
NCT03841110 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37
Last updated 2023-05-01
Summary
FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in participants with advanced solid tumors.
Conditions
- Advanced Solid Tumors
- Lymphoma
- Gastric Cancer
- Colorectal Cancer
- Head and Neck Cancer
- Squamous Cell Carcinoma
- EGFR Positive Solid Tumor
- HER2-positive Breast Cancer
- Hepatocellular Carcinoma
- Small Cell Lung Cancer
- Renal Cell Carcinoma
- Pancreas Cancer
- Melanoma
- NSCLC
- Urothelial Carcinoma
- Cervical Cancer
- Microsatellite Instability
- Merkel Cell Carcinoma
Interventions
- DRUG
-
FT500
FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy
- DRUG
-
Immune Checkpoint Inhibitor
- DRUG
-
Immune Checkpoint Inhibitor
- DRUG
-
Immune Checkpoint Inhibitor
- DRUG
-
Lympho-conditioning agent
- DRUG
-
Lympho-conditioning agent
- DRUG
-
IL-2
Biologic response modifier
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Fate Trial Disclosure · [email protected]
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-02-15
- Primary Completion
- 2022-11-15
- Completion
- 2022-11-15
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
NCT03935893 ·Status: RECRUITING ·Phase: PHASE2
-
Study of IMC-11F8 in Participants With Advanced Solid Tumors
NCT01088464 ·Status: COMPLETED ·Phase: PHASE1
-
Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression
NCT04957615 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT01174121 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC
NCT04521075 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
NCT03169764 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
NCT00509288 ·Status: COMPLETED ·Phase: PHASE2
-
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
NCT03474497 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML
NCT03081780 ·Status: COMPLETED ·Phase: PHASE1
-
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
NCT02721732 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of a Personalized Neoantigen Cancer Vaccine
NCT03639714 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
NCT05098210 ·Status: RECRUITING ·Phase: PHASE1
-
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
NCT00841191 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma
NCT00091143 ·Status: COMPLETED ·Phase: PHASE1
-
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
NCT00066651 ·Status: COMPLETED ·Phase: PHASE1
-
Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy
NCT00801177 ·Status: COMPLETED ·Phase: PHASE1
-
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
NCT03809624 ·Status: TERMINATED ·Phase: PHASE1
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
NCT01993719 ·Status: COMPLETED ·Phase: PHASE2
-
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
NCT00923195 ·Status: COMPLETED ·Phase: PHASE2
-
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
NCT02111863 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
NCT03970382 ·Status: SUSPENDED ·Phase: PHASE1
-
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
NCT03388632 ·Status: COMPLETED ·Phase: PHASE1
-
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
NCT01583686 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
NCT00080353 ·Status: COMPLETED ·Phase: PHASE2
-
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
NCT06151847 ·Status: COMPLETED ·Phase: PHASE2